Ann Arbor, Michigan - Biotectix, LLC has announced the receipt of the Frost & Sullivan 2011 North American Enabling Technology Award for Biopolymers in Neurotechnology Device Applications. The award is granted based on the assessment of several business criteria including product enhancement and enablement, market acceptance, and breadth of technology. Biotectix's performance was quantitatively analyzed and compared with other peer biomaterials companies in these areas.
"The Enabling Technology Award is a prestigious recognition of Biotectix's accomplishments in the field of advanced polymers for implantable medical devices," remarked Dr. James Arps, Vice-President and General Manager at Biotectix. "Frost & Sullivan is a globally recognized leader in identifying new, revolutionary technologies and their recognition is a wonderful validation of the innovative work being carried out by the company's founders and our technical staff."
Biotectix's lead product, BT DOT, is a proprietary conductive polymer coating that dramatically improves the performance of electro stimulation and sensing devices by lowering impedance, providing smaller electrode profiles, and extending battery life. The coating is now commercially available for neural microarrays used in the research market as well as custom and prototype devices.
"Among several new polymeric materials available in the market that are promising enough to enhance the functionality of neural interfaces, Frost & Sullivan feels that Biotectix's BT DOT coating stands out as a unique material for electrode-tissue integration," stated Prasanna Kannan, Industry Analyst for Medical Devices and Surgical Patient Care. "Biotectix's solution provides a superior, highly effective surface area that facilitates charge transfer from electrode surfaces and may also enable new products in key medical device growth areas such as cardiac rhythm management and peripheral nerve stimulation."
Biotectix is developing a new class of conductive polymer materials and coatings for implantable devices and sensors that improve the safety, longevity, reliability, biological integration, and function of implantable biomedical devices. A number of benefits are driven by this platform technology without changing device size, shape, or implant procedure, including improved electrical performance, biocompatibility, and tissue response.
The technology addresses key limitations faced by the medical device industry including foreign body reactions, component stability, and long-term electrical performance in vivo. The materials are custom-designed for the specialized mechanical, electrical, and biological environments of the body, and provide an extremely high level of functional interfacing for medical electrodes.
Biotectix was formed by Allied Minds, a private equity company, based on technology originally developed at the University of Michigan, Ann Arbor. The founders and inventors continue to develop and validate the technology through research, collaborations, and partnerships with leading companies and research institutions.
About Allied Minds
Allied Minds is a private equity-funded innovation company that forms, funds, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. We serve as a diversified holding company that supports our businesses with capital, management and shared services. Allied Minds is the premier firm to utilize this novel and fully-integrated approach to technology commercialization. Our investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline and groundbreaking products and services. Our subsidiaries include BA Logix, Biotectix, Cephalogics, CryoXtract, Illumasonix, ProGDerm, Precision Biopsy, Purtein, RF Biocidics, SaltCheck, SciFluor Life Sciences, SiEnergy Systems, SoundCure and Spin Transfer Technologies.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.